James F. Howard Jr., MD, discusses addressing long-standing gaps in seronegative disease care with efgartigimod.

New therapies are changing what is possible in generalised myasthenia gravis care, yet unequal access across Europe continues ...

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing ...

The FDA has granted Priority Review to cemdisiran, a subcutaneously administered siRNA targeting C5 for anti-AChR antibody-positive generalized myasthenia gravis.

Regeneron (REGN) and Alnylam Pharmaceuticals (ALNY) stock are in focus as myasthenia gravis therapy cemdisiran undergoes U.S. and EU reviews. Read more here.

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the use of nipocalimab (Imaavy, Janssen) to treat adults and adolescents aged 12 and over with generalised myasthenia ...

Recent announcements from TG Therapeutics have buoyed optimism on the long-term potential of its Briumvi drug.

Meron siyang myasthenia gravis na ayon sa mayoclinic.com ay walang gamot – Myasthenia gravis is a condition that happens when ...

(janulla/Getty Images) There's a small fatty gland that sits behind your sternum and is often said to be 'useless' in adulthood. Research, however, suggests the thymus gland is not nearly as ...

TG Therapeutics stock is on an absolute rampage, climbing 79% in roughly the first six months of the year, as the biotech takes on Roche.

The firm submitted applications based on data from the Phase III NIMBLE trial, in which cemdisiran improved patients' ability to do daily tasks.

As a chronic autoimmune neuromuscular disorder, myasthenia gravis (MG) causes muscle weakness and severe fatigue that worsens over time if untreated. Experts once discouraged people with MG from ...